Fort Washington Investment Advisors Inc. OH Grows Holdings in NuVasive, Inc. (NUVA)

Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of NuVasive, Inc. (NASDAQ:NUVA) by 10.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 466,507 shares of the medical device company’s stock after buying an additional 45,000 shares during the period. Fort Washington Investment Advisors Inc. OH owned approximately 0.91% of NuVasive worth $23,120,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in NUVA. SG Americas Securities LLC lifted its holdings in shares of NuVasive by 5.0% in the fourth quarter. SG Americas Securities LLC now owns 25,321 shares of the medical device company’s stock worth $1,255,000 after buying an additional 1,204 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of NuVasive by 66.3% in the fourth quarter. Rhumbline Advisers now owns 163,560 shares of the medical device company’s stock worth $8,106,000 after buying an additional 65,200 shares in the last quarter. Advisors Asset Management Inc. lifted its holdings in shares of NuVasive by 8.8% in the fourth quarter. Advisors Asset Management Inc. now owns 17,667 shares of the medical device company’s stock worth $876,000 after buying an additional 1,435 shares in the last quarter. Vaughan Nelson Investment Management L.P. lifted its holdings in shares of NuVasive by 2.8% in the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 317,865 shares of the medical device company’s stock worth $15,754,000 after buying an additional 8,790 shares in the last quarter. Finally, Signition LP purchased a new stake in shares of NuVasive in the fourth quarter worth about $973,000.

A number of equities research analysts have recently issued reports on NUVA shares. BidaskClub downgraded shares of NuVasive from a “strong-buy” rating to a “buy” rating in a report on Friday, December 7th. ValuEngine raised shares of NuVasive from a “hold” rating to a “buy” rating in a report on Wednesday, November 21st. Canaccord Genuity lowered their price target on shares of NuVasive from $80.00 to $75.00 and set a “buy” rating on the stock in a report on Wednesday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 target price (down from $80.00) on shares of NuVasive in a research note on Wednesday, October 31st. Finally, BTIG Research lowered their target price on shares of NuVasive to $59.00 and set a “buy” rating on the stock in a research note on Thursday, January 17th. They noted that the move was a valuation call. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $64.00.

In other NuVasive news, insider Matthew Link sold 4,889 shares of NuVasive stock in a transaction that occurred on Wednesday, November 21st. The shares were sold at an average price of $62.22, for a total transaction of $304,193.58. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 8,671 shares of company stock worth $538,741 over the last three months. Insiders own 0.95% of the company’s stock.

NUVA stock opened at $49.55 on Monday. The company has a market cap of $2.55 billion, a price-to-earnings ratio of 25.94, a price-to-earnings-growth ratio of 1.33 and a beta of 1.12. NuVasive, Inc. has a one year low of $43.51 and a one year high of $72.41. The company has a current ratio of 3.45, a quick ratio of 1.83 and a debt-to-equity ratio of 0.74.

ILLEGAL ACTIVITY WARNING: This article was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2019/02/11/fort-washington-investment-advisors-inc-oh-grows-holdings-in-nuvasive-inc-nuva.html.

About NuVasive

NuVasive, Inc, a medical device company, develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal product is Maximum Access Surgery, a minimally-disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.

Featured Article: Stochastic Momentum Index (SMI)

Want to see what other hedge funds are holding NUVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NuVasive, Inc. (NASDAQ:NUVA).

Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply